Business
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — —
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"text","content":"— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — — Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients — RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a corporate update. “The successful launch of ORLADEYO, the rapid advancement of our pipeline and the additional capital we acquired last year have transformed BioCryst. With more than $500 million on our balance sheet and ORLADEYO revenue growing to no less than $250 million in 2022, and $1 billion in global peak sales, we are focused on compounding the value of the company by allocating capital to grow ORLADEYO and advancing our complement program to get our oral drugs to patients suffering from many different rare diseases,” said Jon Stonehouse, president and chief executive officer of BioCryst. Program Updates and Key Milestones ORLADEYO® (berotralstat): Oral, Once-daily Treatment for Prevention of Hereditary Angioedema (HAE) Attacks U.S. Launch ORLADEYO net revenue in the fourth quarter of 2021 was $46.2 million. New patient demand for ORLADEYO remains strong and consistent, with a similar number of new patients added in Q4 2021 as in each of the previous three quarters of the year. Patients switching from other prophylactic therapies and acute-only therapy continue to drive the launch. More than half of patients new to ORLADEYO since launch had a previous prophylactic medicine prior to ORLADEYO and most of the remainder were from acute-only treatment.Most patients are well-controlled on ORLADEYO and remain on therapy. Approximately 70 percent of patients starting ORLADEYO, including those switching from injectable prophylaxis, remain on ORLADEYO in the first year. The ORLADEYO prescriber base continues to grow significantly as physicians gain real-world experience. In market research, 60 U.S. physicians, who treat an average of seven HAE patients each, reported that they expect to double their use of ORLADEYO, and that ORLADEYO will become their most prescribed prophylactic treatment in the next 12 months.ORLADEYO is now covered by all major payors an...